Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program

JAMA Intern Med. 2013 May 13;173(9):817-9. doi: 10.1001/jamainternmed.2013.3004.
No abstract available

Publication types

  • Letter
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Benzazepines / administration & dosage
  • Benzazepines / adverse effects*
  • Bupropion / administration & dosage
  • Bupropion / adverse effects*
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology*
  • Dopamine Uptake Inhibitors / administration & dosage
  • Dopamine Uptake Inhibitors / adverse effects*
  • Drug Prescriptions
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nicotinic Agonists / administration & dosage
  • Nicotinic Agonists / adverse effects*
  • Product Surveillance, Postmarketing*
  • Quinoxalines / administration & dosage
  • Quinoxalines / adverse effects*
  • Risk Assessment
  • Risk Factors
  • Sentinel Surveillance*
  • Smoking Cessation / methods*
  • Tobacco Use Disorder / drug therapy
  • United States
  • United States Food and Drug Administration
  • Varenicline

Substances

  • Benzazepines
  • Dopamine Uptake Inhibitors
  • Nicotinic Agonists
  • Quinoxalines
  • Bupropion
  • Varenicline